0001157523-22-001193.txt : 20220908 0001157523-22-001193.hdr.sgml : 20220908 20220908091458 ACCESSION NUMBER: 0001157523-22-001193 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220908 FILED AS OF DATE: 20220908 DATE AS OF CHANGE: 20220908 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoPrecise Antibodies Ltd. CENTRAL INDEX KEY: 0001715925 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39530 FILM NUMBER: 221232701 BUSINESS ADDRESS: STREET 1: 880 - 580 HORNBY STREET CITY: VANCOUVER STATE: A1 ZIP: V6C3B6 BUSINESS PHONE: 6048060626 MAIL ADDRESS: STREET 1: 880 - 580 HORNBY STREET CITY: VANCOUVER STATE: A1 ZIP: V6C3B6 6-K 1 a52875099.htm IMMUNOPRECISE ANTIBODIES LTD. 6-K
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of September 2022
 
Commission File Number: 001-39530
 
ImmunoPrecise Antibodies Ltd.
(Translation of registrant’s name into English)
 
3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8
(Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☐ Form 40-F  ☒
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
 
 x
EXHIBIT INDEX
 
Exhibit No.
 
Description
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
IMMUNOPRECISE ANTIBODIES LTD.
 
 
 
Date: September 8, 2022
By:
/s/ Brad McConn
 
 
Brad McConn
 
 
Chief Financial Officer
 
 
 
 
 EX-99.1 2 a52875099ex99_1.htm EXHIBIT 99.1
Exhibit 99.1

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022

The Company to host an earnings conference call via webcast

VICTORIA, British Columbia--(BUSINESS WIRE)--September 8, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.

ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested in submitting questions ahead of the call are encouraged to email the Company’s investor relations contact.

Conference Call:

Date: Wednesday, September 14, 2022
Time: 10:30 am Eastern time

Participant Info:

Conference ID: 9236374
Participant Toll-Free Dial-In Number: 1 (888) 550-5658
Participant Toll Dial-In Number: 1 (646) 960-0289

Attendee URL: https://events.q4inc.com/attendee/349012238

The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at https://www.immunoprecise.com/investors.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company's periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and technology company that leverages network biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com

Contacts

Investor contact: investors@immunoprecise.com